GSK Agrees to Pay Up to $2.2B to Settle 80K Zantac Lawsuits

Published OCT 10 2024

story

Above: GlaxoSmithKline (GSk) headquarters in London. Image copyright: JUSTIN TALLIS/Contributor/AFP via Getty Images

The Spin

GSK's decision to settle these cases simply avoids the distraction of protracted litigation. There's no scientific evidence backing claims of consumer harm from Zantac. The company will continue defending itself in all other Zantac cases based on facts and science.

GSK

The settlements indicate GSK's awareness of potential liability. The FDA's findings that Zantac produces NDMA over time, which can cause cancer in large quantities, support the plaintiffs' claims. The massive number of pending lawsuits suggests widespread concern about the drug's safety.

Bloomberg.com

There's a 50% chance that the average survival rate of all cancers will exceed 75% by 2029, according to the Metaculus prediction community.

BBC News